Matthew R Henn sold $3,204 of MCRB
See Remarks at Seres Therapeutics, Inc.. 3,953 shares at an average of $0.81, traded Feb 18, 2025, filed Feb 19, 2025.
Score components
- +15RoleOfficer
- 0Trade size$3k at market
- 0Share of holdings soldSold 4.5% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-023580, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 15, 2025 | MOption exercise Common Stock10b5-1 | +2,813 | - | - | 80,583 | Feb 19, 2025 |
| Feb 15, 2025 | MOption exercise Common Stock10b5-1 | +7,813 | - | - | 88,396 | Feb 19, 2025 |
| Feb 18, 2025 | SOpen-market sale Common Stock10b5-1 | -3,953 | $0.81 | $3,204 | 84,443 | Feb 19, 2025 |
| Feb 15, 2025 | MOption exercise Restricted Stock Unitsderivative10b5-1 | -2,813 | $0.00 | $0 | 22,500 | Feb 19, 2025 |
| Feb 15, 2025 | MOption exercise Restricted Stock Unitsderivative10b5-1 | -7,813 | $0.00 | $0 | 23,437 | Feb 19, 2025 |
Related signals
Other insiders at Seres Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | Seres Therapeutics, Inc. | Thomas DesRosier See Remarks | $1,265 76 shares | -1% | |
| 0Weak | Seres Therapeutics, Inc. | Matthew R Henn See Remarks | $1,215 73 shares | -2% | |
| 0Weak | Seres Therapeutics, Inc. | Thomas DesRosier Chief Legal Officer and EVP | $575 79 shares | -1% | |
| 0Weak | Seres Therapeutics, Inc. | Matthew R Henn See Remarks | $561 77 shares | -2% | |
| 5Weak | Seres Therapeutics, Inc. | Eric D. Shaff CEO and President | $1,602 220 shares | -2% | |
| 0Weak | Seres Therapeutics, Inc. | Teresa L. Young See Remarks | $459 63 shares | -1% | |
| 0Weak | Seres Therapeutics, Inc. | Thomas DesRosier Chief Legal Officer and EVP | $3,485 4,300 shares | -3% | |
| 0Weak | Seres Therapeutics, Inc. | Thomas DesRosier Chief Legal Officer and EVP | $475 878 shares | -1% | |
| 0Weak | Seres Therapeutics, Inc. | Matthew R Henn See Remarks | $501 927 shares | -1% | |
| 5Weak | Seres Therapeutics, Inc. | Eric D. Shaff CEO and President | $1,355 2,505 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.